Zhu Zhaozhong, Liang Liming, Zhang Ruyang, Wei Yongyue, Su Li, Tejera Paula, Guo Yichen, Wang Zhaoxi, Lu Quan, Baccarelli Andrea A, Zhu Xi, Bajwa Ednan K, Taylor Thompson B, Shi Guo-Ping, Christiani David C
Department of Environmental Health, Harvard T.H. Chan School of Public Health, 665 Huntington Avenue, Boston, MA, USA.
Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Intensive Care Med Exp. 2017 Aug 30;5(1):38. doi: 10.1186/s40635-017-0155-0.
MicroRNAs (miRNAs) can play important roles in inflammation and infection, which are common manifestations of acute respiratory distress syndrome (ARDS). We assessed if whole blood miRNAs were potential diagnostic biomarkers for human ARDS.
This nested case-control study (N = 530) examined a cohort of ARDS patients and critically ill at-risk controls. Whole blood miRNA profiles and logistic regression analyses identified miRNAs correlated with ARDS. Stratification analysis also assessed selected miRNA markers for their role in sepsis and pneumonia associated with ARDS. Receiver operating characteristic (ROC) analysis evaluated miRNA diagnostic performance, along with Lung Injury Prediction Score (LIPS).
Statistical analyses were performed on 294 miRNAs, selected from 754 miRNAs after quality control screening. Logistic regression identified 22 miRNAs from a 156-patient discovery cohort as potential risk or protective markers of ARDS. Three miRNAs-miR-181a, miR-92a, and miR-424-from the discovery cohort remained significantly associated with ARDS in a 373-patient independent validation cohort (FDR q < 0.05) and meta-analysis (p < 0.001). ROC analyses demonstrated a LIPS baseline area-under-the-curve (AUC) value of ARDS of 0.708 (95% CI 0.651-0.766). Addition of miR-181a, miR-92a, and miR-424 to LIPS increased baseline AUC to 0.723 (95% CI 0.667-0.778), with a relative integrated discrimination improvement of 2.40 (p = 0.005) and a category-free net reclassification index of 27.21% (p = 0.01).
miR-181a and miR-92a are risk biomarkers for ARDS, whereas miR-424 is a protective biomarker. Addition of these miRNAs to LIPS can improve the risk estimate for ARDS.
微小RNA(miRNA)可在炎症和感染中发挥重要作用,而炎症和感染是急性呼吸窘迫综合征(ARDS)的常见表现。我们评估了全血miRNA是否为人类ARDS的潜在诊断生物标志物。
这项巢式病例对照研究(N = 530)对一组ARDS患者和危重症风险对照进行了检查。全血miRNA谱和逻辑回归分析确定了与ARDS相关的miRNA。分层分析还评估了所选miRNA标志物在与ARDS相关的脓毒症和肺炎中的作用。受试者操作特征(ROC)分析评估了miRNA的诊断性能,以及肺损伤预测评分(LIPS)。
对经过质量控制筛选后从754个miRNA中选出的294个miRNA进行了统计分析。逻辑回归从一个156例患者的发现队列中确定了22个miRNA作为ARDS的潜在风险或保护标志物。来自发现队列的3个miRNA——miR-181a、miR-92a和miR-424——在一个373例患者的独立验证队列(FDR q < 0.05)和荟萃分析(p < 0.001)中仍与ARDS显著相关。ROC分析显示ARDS的LIPS基线曲线下面积(AUC)值为0.708(95%CI 0.651 - 0.766)。将miR-181a、miR-92a和miR-424添加到LIPS中可使基线AUC增加到0.723(95%CI 0.667 - 0.778),相对综合辨别改善为2.40(p = 0.005),无类别净重新分类指数为27.21%(p = 0.01)。
miR-181a和miR-92a是ARDS的风险生物标志物,而miR-424是一种保护生物标志物。将这些miRNA添加到LIPS中可改善ARDS的风险估计。